Literature DB >> 3194863

Immunoregulatory properties of pulmonary surfactant: effect of lung lining fluid on proliferation of human blood lymphocytes.

M L Wilsher1, D A Hughes, P L Haslam.   

Abstract

Human pulmonary surfactant has not been shown to have immunoregulatory properties. A study was designed to examine the effect of whole surfactant (lyophilised bronchoalveolar lavage fluid) and purified surfactant lipids obtained from normal lungs of three species (man, pig, rabbit) on the lymphoproliferative responses of human peripheral blood lymphocytes to mitogens and alloantigens. Whole surfactant and purified surfactant lipids suppressed the proliferative response to phytohaemagglutinin in a dose dependent manner. The purified lipid fraction appeared to cause more suppression than whole surfactant in all the species. There was significant suppression of the proliferative response to B cell mitogens, T cell mitogens (pokeweed mitogen and phytohaemagglutinin), and alloantigens as tested by allogeneic mixed lymphocyte cultures. These results suggest an immunoregulatory role for pulmonary surfactant, most likely due to the lipid fraction.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3194863      PMCID: PMC461245          DOI: 10.1136/thx.43.5.354

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  16 in total

1.  A rapid method of total lipid extraction and purification.

Authors:  E G BLIGH; W J DYER
Journal:  Can J Biochem Physiol       Date:  1959-08

2.  Immunosuppressive activity of canine pulmonary surface active material.

Authors:  M J Ansfield; H B Kaltreider; B J Benson; J L Caldwell
Journal:  J Immunol       Date:  1979-03       Impact factor: 5.422

3.  Regulatory serum lipoproteins: regulation of lymphocyte stimulation by a species of low density lipoprotein.

Authors:  L K Curtiss; T S Edgington
Journal:  J Immunol       Date:  1976-05       Impact factor: 5.422

4.  Effect of LDL-In, a normal immunoregulatory human serum low density lipoprotein, on the interaction of macrophages with lymphocytes proliferating in response to mitogen and allogeneic stimulation.

Authors:  L K Curtiss; T S Edgington
Journal:  J Immunol       Date:  1977-06       Impact factor: 5.422

5.  Inhibition of lymphocyte proliferation stimulated by lectins and allogeneic cells by normal plasma lipoproteins.

Authors:  J H Morse; L D Witte; D S Goodman
Journal:  J Exp Med       Date:  1977-12-01       Impact factor: 14.307

6.  Physical and physiological properties of dry lung surfactant.

Authors:  C J Morley; A D Banhham; P Johnson; G D Thorburn; G Jenkin
Journal:  Nature       Date:  1978-01-12       Impact factor: 49.962

7.  Direct suppression of lymphocyte induction by the immunoregulatory human serum low density lipoprotein, LDL-In.

Authors:  D K Fujii; T S Edgington
Journal:  J Immunol       Date:  1980-01       Impact factor: 5.422

8.  Peturbation of lymphocyte response to concanavalin A by exogenous cholesterol and lecithin.

Authors:  B Rivnay; A Globerson; M Shinitzky
Journal:  Eur J Immunol       Date:  1978-03       Impact factor: 5.532

9.  Human alveolar macrophage support of lymphocyte responses to mitogens and antigens. Analysis and comparison with autologous peripheral-blood-derived monocytes and macrophages.

Authors:  D B Ettensohn; N J Roberts
Journal:  Am Rev Respir Dis       Date:  1983-09

10.  Identification of the immunosuppressive components of canine pulmonary surface active material.

Authors:  M J Ansfield; B J Benson
Journal:  J Immunol       Date:  1980-09       Impact factor: 5.422

View more
  14 in total

1.  Dipalmitoylphosphatidylcholine modulates inflammatory functions of monocytic cells independently of mitogen activated protein kinases.

Authors:  A Tonks; R H Morris; A J Price; A W Thomas; K P Jones; S K Jackson
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

2.  In vivo levels and in vitro production of interferon-gamma in fibrosing interstitial lung diseases.

Authors:  C Prior; P L Haslam
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

3.  Regulation of T-cell activation in the lung: isolated lung T cells exhibit surface phenotypic characteristics of recent activation including down-modulated T-cell receptors, but are locked into the G0/G1 phase of the cell cycle.

Authors:  D Strickland; U R Kees; P G Holt
Journal:  Immunology       Date:  1996-02       Impact factor: 7.397

4.  Immunosuppression by pulmonary surfactant: mechanisms of action.

Authors:  M L Wilsher; D J Parker; P L Haslam
Journal:  Thorax       Date:  1990-01       Impact factor: 9.139

5.  Selective inhibition of T cell proliferation but not expression of effector function by human alveolar macrophages.

Authors:  J W Upham; D H Strickland; B W Robinson; P G Holt
Journal:  Thorax       Date:  1997-09       Impact factor: 9.139

6.  Immunomodulatory effects of pulmonary surfactant on natural killer cell and antibody-dependent cytotoxicity.

Authors:  M L Wilsher; D A Hughes; P L Haslam
Journal:  Clin Exp Immunol       Date:  1988-12       Impact factor: 4.330

7.  Aberrant lung remodeling in a mouse model of surfactant dysregulation induced by modulation of the Abca3 gene.

Authors:  Michael F Beers; Lars Knudsen; Yaniv Tomer; Julian Maronn; Ming Zhao; Matthias Ochs; Surafel Mulugeta
Journal:  Ann Anat       Date:  2016-12-26       Impact factor: 2.698

8.  Pulmonary surfactant inhibits activation of human monocytes by recombinant interferon-gamma.

Authors:  M F Geertsma; W L Teeuw; P H Nibbering; R van Furth
Journal:  Immunology       Date:  1994-07       Impact factor: 7.397

9.  Protective role of the lung collectins surfactant protein A and surfactant protein D in airway inflammation.

Authors:  Angela Haczku
Journal:  J Allergy Clin Immunol       Date:  2008-11       Impact factor: 10.793

Review 10.  SP-D and regulation of the pulmonary innate immune system in allergic airway changes.

Authors:  L R Forbes; A Haczku
Journal:  Clin Exp Allergy       Date:  2010-04       Impact factor: 5.018

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.